The absorption of drugA can be decreased when combined with drugB	0
The bioavailability of drugA can be decreased when combined with drugB	1
The bioavailability of drugA can be increased when combined with drugB	2
The metabolism of drugA can be decreased when combined with drugB	3
The metabolism of drugA can be increased when combined with drugB	4
The protein binding of drugA can be decreased when combined with drugB	5
The risk of a hypersensitivity reaction to drugA is increased when it is combined with drugB	6
The risk or severity of QTc prolongation can be increased when drugA is combined with drugB	7
The risk or severity of adverse effects can be increased when drugA is combined with drugB	8
The risk or severity of bleeding can be increased when drugA is combined with drugB	9
The risk or severity of heart failure can be increased when drugA is combined with drugB	10
The risk or severity of hyperkalemia can be increased when drugA is combined with drugB	11
The risk or severity of hypertension can be increased when drugA is combined with drugB	12
The risk or severity of hypotension can be increased when drugA is combined with drugB	13
The serum concentration of drugA can be decreased when it is combined with drugB	14
The serum concentration of drugA can be increased when it is combined with drugB	15
The serum concentration of the active metabolites of drugA can be increased when drugA is used in combination with drugB	16
The serum concentration of the active metabolites of drugA can be reduced when drugA is used in combination with drugB resulting in a loss in efficacy	17
The therapeutic efficacy of drugA can be decreased when used in combination with drugB	18
The therapeutic efficacy of drugA can be increased when used in combination with drugB	19
drugA can cause a decrease in the absorption of drugB resulting in a reduced serum concentration and potentially a decrease in efficacy	20
drugA can cause an increase in the absorption of drugB resulting in an increased serum concentration and potentially a worsening of adverse effects	21
drugA may decrease effectiveness of drugB as a diagnostic agent	22
drugA may decrease the analgesic activities of drugB	23
drugA may decrease the anticoagulant activities of drugB	24
drugA may decrease the antihypertensive activities of drugB	25
drugA may decrease the antiplatelet activities of drugB	26
drugA may decrease the bronchodilatory activities of drugB	27
drugA may decrease the cardiotoxic activities of drugB	28
drugA may decrease the diuretic activities of drugB	29
drugA may decrease the excretion rate of drugB which could result in a higher serum level	30
drugA may decrease the neuromuscular blocking activities of drugB	31
drugA may decrease the sedative activities of drugB	32
drugA may decrease the stimulatory activities of drugB	33
drugA may decrease the vasoconstricting activities of drugB	34
drugA may increase the QTc-prolonging activities of drugB	35
drugA may increase the adverse neuromuscular activities of drugB	36
drugA may increase the analgesic activities of drugB	37
drugA may increase the anticholinergic activities of drugB	38
drugA may increase the anticoagulant activities of drugB	39
drugA may increase the antihypertensive activities of drugB	40
drugA may increase the antiplatelet activities of drugB	41
drugA may increase the antipsychotic activities of drugB	42
drugA may increase the arrhythmogenic activities of drugB	43
drugA may increase the atrioventricular blocking (AV block) activities of drugB	44
drugA may increase the bradycardic activities of drugB	45
drugA may increase the bronchoconstrictory activities of drugB	46
drugA may increase the cardiotoxic activities of drugB	47
drugA may increase the central nervous system depressant (CNS depressant) activities of drugB	48
drugA may increase the central nervous system depressant (CNS depressant) and hypertensive activities of drugB	49
drugA may increase the central neurotoxic activities of drugB	50
drugA may increase the constipating activities of drugB	51
drugA may increase the dermatologic adverse activities of drugB	52
drugA may increase the excretion rate of drugB which could result in a lower serum level and potentially a reduction in efficacy	53
drugA may increase the fluid retaining activities of drugB	54
drugA may increase the hepatotoxic activities of drugB	55
drugA may increase the hypercalcemic activities of drugB	56
drugA may increase the hyperglycemic activities of drugB	57
drugA may increase the hyperkalemic activities of drugB	58
drugA may increase the hypertensive activities of drugB	59
drugA may increase the hypocalcemic activities of drugB	60
drugA may increase the hypoglycemic activities of drugB	61
drugA may increase the hypokalemic activities of drugB	62
drugA may increase the hyponatremic activities of drugB	63
drugA may increase the hypotensive activities of drugB	64
drugA may increase the hypotensive and central nervous system depressant (CNS depressant) activities of drugB	65
drugA may increase the immunosuppressive activities of drugB	66
drugA may increase the myelosuppressive activities of drugB	67
drugA may increase the myopathic rhabdomyolysis activities of drugB	68
drugA may increase the nephrotoxic activities of drugB	69
drugA may increase the neuroexcitatory activities of drugB	70
drugA may increase the neuromuscular blocking activities of drugB	71
drugA may increase the neurotoxic activities of drugB	72
drugA may increase the orthostatic hypotensive activities of drugB	73
drugA may increase the ototoxic activities of drugB	74
drugA may increase the photosensitizing activities of drugB	75
drugA may increase the respiratory depressant activities of drugB	76
drugA may increase the sedative activities of drugB	77
drugA may increase the serotonergic activities of drugB	78
drugA may increase the stimulatory activities of drugB	79
drugA may increase the tachycardic activities of drugB	80
drugA may increase the thrombogenic activities of drugB	81
drugA may increase the ulcerogenic activities of drugB	82
drugA may increase the vasoconstricting activities of drugB	83
drugA may increase the vasodilatory activities of drugB	84
drugA may increase the vasopressor activities of drugB	85
